Lung Cancer Liquid Biopsy Market Size, Share, and Outlook, H2-2025 Report- By Biomarker (CTC (Circulating Tumor Cells), ctDNA (Circulating tumor DNA), Exosomes and RNA), By Application (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By End-User (Dia
Description
Lung Cancer Liquid Biopsy Market Outlook
The global Lung Cancer Liquid Biopsy Market Size is valued at $1.3 Billion in 2025 and is forecast to reach $3.2 Billion in 2032 at a CAGR of 13.5%.
The Lung Cancer Liquid Biopsy Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Lung Cancer Liquid Biopsy Market segments across 22 countries from 2021 to 2032. Key segments covered include By Biomarker (CTC (Circulating Tumor Cells), ctDNA (Circulating tumor DNA), Exosomes and RNA), By Application (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By End-User (Diagnostic and Imaging Centres, Hospitals, Academic and Research Centers, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Lung Cancer Liquid Biopsy Market Insights, 2025
The lung cancer liquid biopsy market in 2025 represents a rapidly growing segment within precision oncology, offering minimally invasive alternatives to tissue biopsies for tumor genotyping, early detection, and treatment monitoring. Circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomal biomarkers are increasingly utilized to identify actionable mutations such as EGFR, ALK, and ROS1, enabling personalized targeted therapies. Advances in next-generation sequencing (NGS) platforms and digital PCR technologies have improved assay sensitivity and specificity, critical for early-stage detection and minimal residual disease monitoring. Regulatory approvals and clinical guidelines are progressively endorsing liquid biopsy as a complement to standard tissue diagnostics, particularly in cases where invasive biopsy is contraindicated. The market benefits from rising lung cancer incidence, growing adoption of immunotherapy, and the need for real-time monitoring of acquired resistance mutations. Challenges include standardization of pre-analytical variables, assay harmonization, and reimbursement complexities. Integration with electronic health records and bioinformatics pipelines is enhancing data interpretation and clinical decision-making.
Five Trends Shaping the Global Lung Cancer Liquid Biopsy Market in 2025 and Beyond
The global Lung Cancer Liquid Biopsy Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Lung Cancer Liquid Biopsy Industry?
The Lung Cancer Liquid Biopsy Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Lung Cancer Liquid Biopsy Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Lung Cancer Liquid Biopsy Market Segment Insights
The Lung Cancer Liquid Biopsy Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Biomarker (CTC (Circulating Tumor Cells), ctDNA (Circulating tumor DNA), Exosomes and RNA), By Application (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By End-User (Diagnostic and Imaging Centres, Hospitals, Academic and Research Centers, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Lung Cancer Liquid Biopsy Industry Value Chain
The chapter identifies potential companies and their operations across the global Lung Cancer Liquid Biopsy Industry ecosystem. It assists decision-makers in evaluating global Lung Cancer Liquid Biopsy Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Lung Cancer Liquid Biopsy Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Lung Cancer Liquid Biopsy Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Lung Cancer Liquid Biopsy Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Lung Cancer Liquid Biopsy Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Lung Cancer Liquid Biopsy Market.
Europe Lung Cancer Liquid Biopsy Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Lung Cancer Liquid Biopsy Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Lung Cancer Liquid Biopsy Industry competitiveness. The report analyses the key Lung Cancer Liquid Biopsy Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Lung Cancer Liquid Biopsy Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Lung Cancer Liquid Biopsy Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Lung Cancer Liquid Biopsy Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Lung Cancer Liquid Biopsy Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Lung Cancer Liquid Biopsy Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Lung Cancer Liquid Biopsy Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Agilent Technologies Inc, Bio-Rad Laboratories Inc, Cardiff Oncology Inc, CareDx, Eurofins Scientific, Exact Sciences Corp, Exosome Diagnostics Inc, F. Hoffmann-La Roche Ltd, Genomic Health Inc, Guardant Health, Illumina Inc, Immucor, LungLife AI Inc, MDxHealth, Menarini Silicon Biosystems, Myriad Genetics Inc, Natera Inc, QIAGEN N.V., Thermo Fisher Scientific Inc. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Lung Cancer Liquid Biopsy Market Scope
Leading Segments
By Biomarker
CTC (Circulating Tumor Cells)
ctDNA (Circulating tumor DNA)
Exosomes and RNA
By Application
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
By End-User
Diagnostic and Imaging Centres
Hospitals
Academic and Research Centers
Others
Leading Companies
Agilent Technologies Inc
Bio-Rad Laboratories Inc
Cardiff Oncology Inc
CareDx
Eurofins Scientific
Exact Sciences Corp
Exosome Diagnostics Inc
F. Hoffmann-La Roche Ltd
Genomic Health Inc
Guardant Health
Illumina Inc
Immucor
LungLife AI Inc
MDxHealth
Menarini Silicon Biosystems
Myriad Genetics Inc
Natera Inc
QIAGEN N.V.
Thermo Fisher Scientific Inc
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Lung Cancer Liquid Biopsy Market Size is valued at $1.3 Billion in 2025 and is forecast to reach $3.2 Billion in 2032 at a CAGR of 13.5%.
The Lung Cancer Liquid Biopsy Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Lung Cancer Liquid Biopsy Market segments across 22 countries from 2021 to 2032. Key segments covered include By Biomarker (CTC (Circulating Tumor Cells), ctDNA (Circulating tumor DNA), Exosomes and RNA), By Application (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By End-User (Diagnostic and Imaging Centres, Hospitals, Academic and Research Centers, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Lung Cancer Liquid Biopsy Market Insights, 2025
The lung cancer liquid biopsy market in 2025 represents a rapidly growing segment within precision oncology, offering minimally invasive alternatives to tissue biopsies for tumor genotyping, early detection, and treatment monitoring. Circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomal biomarkers are increasingly utilized to identify actionable mutations such as EGFR, ALK, and ROS1, enabling personalized targeted therapies. Advances in next-generation sequencing (NGS) platforms and digital PCR technologies have improved assay sensitivity and specificity, critical for early-stage detection and minimal residual disease monitoring. Regulatory approvals and clinical guidelines are progressively endorsing liquid biopsy as a complement to standard tissue diagnostics, particularly in cases where invasive biopsy is contraindicated. The market benefits from rising lung cancer incidence, growing adoption of immunotherapy, and the need for real-time monitoring of acquired resistance mutations. Challenges include standardization of pre-analytical variables, assay harmonization, and reimbursement complexities. Integration with electronic health records and bioinformatics pipelines is enhancing data interpretation and clinical decision-making.
Five Trends Shaping the Global Lung Cancer Liquid Biopsy Market in 2025 and Beyond
The global Lung Cancer Liquid Biopsy Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Lung Cancer Liquid Biopsy Industry?
The Lung Cancer Liquid Biopsy Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Lung Cancer Liquid Biopsy Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Lung Cancer Liquid Biopsy Market Segment Insights
The Lung Cancer Liquid Biopsy Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Biomarker (CTC (Circulating Tumor Cells), ctDNA (Circulating tumor DNA), Exosomes and RNA), By Application (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By End-User (Diagnostic and Imaging Centres, Hospitals, Academic and Research Centers, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Lung Cancer Liquid Biopsy Industry Value Chain
The chapter identifies potential companies and their operations across the global Lung Cancer Liquid Biopsy Industry ecosystem. It assists decision-makers in evaluating global Lung Cancer Liquid Biopsy Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Lung Cancer Liquid Biopsy Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Lung Cancer Liquid Biopsy Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Lung Cancer Liquid Biopsy Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Lung Cancer Liquid Biopsy Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Lung Cancer Liquid Biopsy Market.
Europe Lung Cancer Liquid Biopsy Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Lung Cancer Liquid Biopsy Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Lung Cancer Liquid Biopsy Industry competitiveness. The report analyses the key Lung Cancer Liquid Biopsy Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Lung Cancer Liquid Biopsy Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Lung Cancer Liquid Biopsy Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Lung Cancer Liquid Biopsy Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Lung Cancer Liquid Biopsy Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Lung Cancer Liquid Biopsy Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Lung Cancer Liquid Biopsy Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Agilent Technologies Inc, Bio-Rad Laboratories Inc, Cardiff Oncology Inc, CareDx, Eurofins Scientific, Exact Sciences Corp, Exosome Diagnostics Inc, F. Hoffmann-La Roche Ltd, Genomic Health Inc, Guardant Health, Illumina Inc, Immucor, LungLife AI Inc, MDxHealth, Menarini Silicon Biosystems, Myriad Genetics Inc, Natera Inc, QIAGEN N.V., Thermo Fisher Scientific Inc. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Lung Cancer Liquid Biopsy Market Scope
Leading Segments
By Biomarker
CTC (Circulating Tumor Cells)
ctDNA (Circulating tumor DNA)
Exosomes and RNA
By Application
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
By End-User
Diagnostic and Imaging Centres
Hospitals
Academic and Research Centers
Others
Leading Companies
Agilent Technologies Inc
Bio-Rad Laboratories Inc
Cardiff Oncology Inc
CareDx
Eurofins Scientific
Exact Sciences Corp
Exosome Diagnostics Inc
F. Hoffmann-La Roche Ltd
Genomic Health Inc
Guardant Health
Illumina Inc
Immucor
LungLife AI Inc
MDxHealth
Menarini Silicon Biosystems
Myriad Genetics Inc
Natera Inc
QIAGEN N.V.
Thermo Fisher Scientific Inc
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
193 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Lung Cancer Liquid Biopsy Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Lung Cancer Liquid Biopsy Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Lung Cancer Liquid Biopsy Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Lung Cancer Liquid Biopsy Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Lung Cancer Liquid Biopsy Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Biomarker
- CTC (Circulating Tumor Cells)
- ctDNA (Circulating tumor DNA)
- Exosomes and RNA
- By Application
- Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- By End-User
- Diagnostic and Imaging Centres
- Hospitals
- Academic and Research Centers
- Others
- 6. Global Lung Cancer Liquid Biopsy Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Lung Cancer Liquid Biopsy Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Lung Cancer Liquid Biopsy Market Trends and Growth Opportunities
- 6.2.1 North America Lung Cancer Liquid Biopsy Market Outlook by Type
- 6.2.2 North America Lung Cancer Liquid Biopsy Market Outlook by Application
- 6.3 North America Lung Cancer Liquid Biopsy Market Outlook by Country
- 6.3.1 The US Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 6.3.2 Canada Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 6.3.3 Mexico Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 7. Europe Lung Cancer Liquid Biopsy Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Lung Cancer Liquid Biopsy Market Trends and Growth Opportunities
- 7.2.1 Europe Lung Cancer Liquid Biopsy Market Outlook by Type
- 7.2.2 Europe Lung Cancer Liquid Biopsy Market Outlook by Application
- 7.3 Europe Lung Cancer Liquid Biopsy Market Outlook by Country
- 7.3.2 Germany Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 7.3.3 France Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 7.3.4 The UK Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 7.3.5 Spain Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 7.3.6 Italy Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 7.3.7 Russia Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 8. Asia Pacific Lung Cancer Liquid Biopsy Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Lung Cancer Liquid Biopsy Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Lung Cancer Liquid Biopsy Market Outlook by Type
- 8.2.2 Asia Pacific Lung Cancer Liquid Biopsy Market Outlook by Application
- 8.3 Asia Pacific Lung Cancer Liquid Biopsy Market Outlook by Country
- 8.3.1 China Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 8.3.2 India Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 8.3.3 Japan Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 8.3.4 South Korea Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 8.3.5 Australia Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 8.3.6 South East Asia Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 9. South America Lung Cancer Liquid Biopsy Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Lung Cancer Liquid Biopsy Market Trends and Growth Opportunities
- 9.2.1 South America Lung Cancer Liquid Biopsy Market Outlook by Type
- 9.2.2 South America Lung Cancer Liquid Biopsy Market Outlook by Application
- 9.3 South America Lung Cancer Liquid Biopsy Market Outlook by Country
- 9.3.1 Brazil Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 9.3.2 Argentina Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 10. Middle East and Africa Lung Cancer Liquid Biopsy Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Lung Cancer Liquid Biopsy Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Lung Cancer Liquid Biopsy Market Outlook by Type
- 10.2.2 Middle East and Africa Lung Cancer Liquid Biopsy Market Outlook by Application
- 10.3 Middle East and Africa Lung Cancer Liquid Biopsy Market Outlook by Country
- 10.3.1 Saudi Arabia Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 10.3.2 The UAE Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 10.3.4 South Africa Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 10.3.5 Egypt Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Lung Cancer Liquid Biopsy Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- Agilent Technologies Inc
- Bio-Rad Laboratories Inc
- Cardiff Oncology Inc
- CareDx
- Eurofins Scientific
- Exact Sciences Corp
- Exosome Diagnostics Inc
- F. Hoffmann-La Roche Ltd
- Genomic Health Inc
- Guardant Health
- Illumina Inc
- Immucor
- LungLife AI Inc
- MDxHealth
- Menarini Silicon Biosystems
- Myriad Genetics Inc
- Natera Inc
- QIAGEN N.V.
- Thermo Fisher Scientific Inc
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
